A new research article from Thomas Stewart, an associate professor of data science at the University of Virginia, examining the COVID-19 treatment fluvoxamine has been published in JAMA.
Nov 20, 2023
0
0
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine at a dosage of 100 mg twice daily for ...
Sep 14, 2023
0
0
For high-risk outpatients with COVID-19, treatment with oral fluvoxamine plus budesonide reduces the incidence of severe disease needing advanced care, according to a study published online April 18 in the Annals of Internal ...
Apr 18, 2023
0
2
For patients with mild-to-moderate COVID-19, treatment with fluvoxamine does not improve time to sustained recovery versus placebo, according to a study published online Jan. 12 in Journal of the American Medical Association.
Jan 13, 2023
0
13
A new meta-analysis shows that psychiatric medications can give some protection against COVID-19, with the common antidepressant fluvoxamine showing the strongest effect. Patients taking fluvoxamine showed reduced symptoms, ...
Dec 15, 2022
0
8
A study testing drugs that are used for other conditions for their potential in treating COVID-19 has found that the antidepressant fluvoxamine (brand name Luvox) offered no benefit, at least at an initial smaller dose.
Oct 20, 2022
0
8
The antidepressant drug fluvoxamine and the gout drug colchicine are not recommended for patients with mild or moderate COVID-19 because there is currently insufficient evidence that they improve important outcomes for patients, ...
Jul 13, 2022
0
16
In the first few weeks of the pandemic, when physicians were grappling with the unknown like everyone else, psychiatrist Angela Reiersen recalled that an old drug in her field, called fluvoxamine, affected the body in ways ...
Jan 21, 2022
0
23
The rise of Omicron, the latest SARS-CoV-2 variant of concern, reminds us how quickly things can change during the pandemic.
Dec 9, 2021
0
7
(HealthDay)—For high-risk outpatients with COVID-19, fluvoxamine reduces the need for hospitalization, according to a study published online Oct. 27 in The Lancet Global Health.
Oct 29, 2021
0
3
